Humalog Pen

See also: Generic Humalog, Generic Humalog KwikPen

Humalog Pen is a brand name of insulin lispro, approved by the FDA in the following formulation(s):

HUMALOG PEN (insulin lispro recombinant - injectable; injection)

• 
  Manufacturer: LILLY
  
  Approval date: August 6, 1998
  
  Strength(s): 100 UNITS/ML ^[RLD]

Has a generic version of Humalog Pen been approved?

No. There is currently no therapeutically equivalent version of Humalog Pen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Pen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Insulin analog formulations
  Patent 5,474,978
  Issued: December 12, 1995
  Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
  Assignee(s): Eli Lilly and Company
  The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
    ✓ 
    Patent use: HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
  
  



• 
  Insulin analogs modified at position 29 of the B chain
  Patent 5,514,646
  Issued: May 7, 1996
  Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
  Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
  
  Patent expiration dates:
  
  
  • May 7, 2013
    
    ✓ 
    Patent use: HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
  
  

See also...

• Humalog Cartridge Consumer Information (Cerner Multum)
• Humalog Pen Consumer Information (Cerner Multum)
• Insulin Lispro Cartridges Consumer Information (Wolters Kluwer)
• Insulin Lispro Vials Consumer Information (Wolters Kluwer)
• Insulin lispro Consumer Information (Cerner Multum)
• Lispro-PFC Advanced Consumer Information (Micromedex)
• Insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)
• Insulin lispro, recombinant Subcutaneous Advanced Consumer Information (Micromedex)
• Insulin Lispro AHFS DI Monographs (ASHP)